Purdue deal to rank among biggest in pharma history OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis. Business • 16 Sep 19
Purdue deal to rank among biggest in pharma history OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis. Business • 16 Sep 19
Takeda shareholders approve $59 billion Shire deal Takeda Pharmaceutical shareholders have approved the company's $59 billion takeover of London-listed Shire. Business • 05 Dec 18
Takeda shareholders approve $59 billion Shire deal Takeda Pharmaceutical shareholders have approved the company's $59 billion takeover of London-listed Shire. Business • 05 Dec 18
Takeda gets key US regulatory approval to buy Shire Japan's Takeda Pharmaceutical has received a key US regulatory approval for its $62 billion deal to buy London-listed Shire. Business • 10 Jul 18
Takeda gets key US regulatory approval to buy Shire Japan's Takeda Pharmaceutical has received a key US regulatory approval for its $62 billion deal to buy London-listed Shire. Business • 10 Jul 18
Shire grows earnings by 6%, but holds cautious outlook Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, today reported a 6% rise in first-quarter earnings. Business • 26 Apr 18
Shire grows earnings by 6%, but holds cautious outlook Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, today reported a 6% rise in first-quarter earnings. Business • 26 Apr 18
Shire willing to recommend Takeda's $65 billion offer Rare disease drug maker Shire has said it is willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical to shareholders. Business • 25 Apr 18
Shire willing to recommend Takeda's $65 billion offer Rare disease drug maker Shire has said it is willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical to shareholders. Business • 25 Apr 18
Japan's Takeda nudges up Shire offer to £47 a share Japan's Takeda Pharmaceutical has increased its offer for Shire to $47 a share after its three previous bids - the last at £46.50 - were rejected by the rare-disease drugs specialist. Business • 20 Apr 18
Japan's Takeda nudges up Shire offer to £47 a share Japan's Takeda Pharmaceutical has increased its offer for Shire to $47 a share after its three previous bids - the last at £46.50 - were rejected by the rare-disease drugs specialist. Business • 20 Apr 18
